Baclofen in the Management of Inhalant Withdrawal: A Case Series

Muralidharan, K; Rajkumar, Ravi Philip; Mulla, U; Rb, Nayak; Benegal, Vivek

doi:10.4088/pcc.v10n0108

Cited by 25 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…in reducing the severity of inhalant withdrawal syndrome in 3 young people who had been abusing inhalants for 2 years or more [160]. Baclofen was well tolerated by these subjects.…”

Section: Baclofen and Sudsmentioning

confidence: 99%

Efficacy and Tolerability of Baclofen in Substance Use Disorders: A Systematic Review

Agabio¹,

Preti

Gessa

2013

Eur Addict Res

View full text Add to dashboard Cite

Background: It has been reported that baclofen, a drug used in the treatment of spasticity, reduces the severity of withdrawal symptoms and substance use disorders (SUDs) for some psychoactive drugs. Aims and Methods: To evaluate the effectiveness and safety of baclofen in the treatment of withdrawal syndrome and/or SUDs, providing (1) an outline of its pharmacological features; (2) a summary of studies that have suggested its possible effectiveness in the treatment of SUDs, and (3) a review of randomized, controlled trials (RCTs) on baclofen and SUDs. Results: Baclofen tolerability is generally considered to be good. Eleven RCTs investigated its effectiveness in the treatment of SUDs. Of these, 5 RCTs found that baclofen is effective, 5 RCTs found that it is ineffective and the results of 1 RCT were not appreciable because it did not achieve the preplanned level of participation. Conclusions: The number of RCTs on baclofen and SUDs is still low, and their results are divergent. Further RCTs should be undertaken, particularly with higher doses of baclofen. Its administration may be suggested in patients who fail to respond to other approved drugs or who are affected by liver disease that prevents their administration, or in patients affected by SUDs for which no approved drugs are available. Treatment should be conducted under strict medical supervision.

show abstract

“…in reducing the severity of inhalant withdrawal syndrome in 3 young people who had been abusing inhalants for 2 years or more [160]. Baclofen was well tolerated by these subjects.…”

Section: Baclofen and Sudsmentioning

confidence: 99%

Efficacy and Tolerability of Baclofen in Substance Use Disorders: A Systematic Review

Agabio¹,

Preti

Gessa

2013

Eur Addict Res

View full text Add to dashboard Cite

show abstract

“…Baclofen at 50 mg/day produced a signifi cant reduction of withdrawal symptoms within 48 h of treatment [ 198 ]. This effect may be the result of the action of baclofen at GABA receptors in the ventral tegmental area.…”

Section: Solventsmentioning

confidence: 94%

Substance Abuse

2015

View full text Add to dashboard Cite

“…The only randomized controlled trial found in our search was a study of carbamazepine and haloperidol for the treatment of inhalant-induced psychotic disorder. 4,[7][8][9][10] Appropriate medical care is required for the disorder's sequelae. Vigorous treatment is needed for patients who progress from experimentation to inhalant abuse or dependence.…”

Section: Treatmentmentioning

confidence: 99%